Background: The effect of systemic therapy on malignancy risk among patients with psoriasis is not fully understood.
Psoriasis is a chronic, immune-mediated, inflammatory disease that affects the skin and has important systemic manifestations. 1, 2 In the United States, psoriasis affects nearly 7 million adults age 20 years or older. 3 Results of observational studies and a large meta-analysis have indicated that patients with psoriasis have an increased risk for development of malignancies, including lymphoma and nonmelanoma skin cancer (NMSC), compared with those without psoriasis. [4] [5] [6] [7] [8] [9] [10] Understanding whether the risk for malignancy is attributable to the disease state itself or to immunosuppressive systemic therapy is a key consideration for providers and patients. Data quantifying the effect of treatment on malignancy development on the basis of long-term extensions of clinical trials in psoriasis have not demonstrated increased risk for malignancy with tumor necrosis factor-a (TNF-a) inhibitors (etanercept, adalimumab, infliximab) or the antieinterleukin 12/23 antibody, ustekinumab. [11] [12] [13] [14] [15] Although studies regarding the risk for malignancy with other systemic treatments (eg, methotrexate) are limited in psoriasis, data regarding malignancy risk with long-term exposure to a TNF-a inhibitor in rheumatoid arthritis and across immune-related diseases (including psoriatic arthritis and Crohn's disease) have led to mixed conclusions, with a few studies indicating increased risk. [16] [17] [18] [19] [20] [21] [22] The current study was conducted using data from the large, disease-based Psoriasis Longitudinal Assessment and Registry (PSOLAR) of patients with psoriasis. Previous PSOLAR analyses using safety surveillance methodologies and safety data from smaller registries, including Biobadaderm and PsoBEST, suggest no association between use of conventional systemic therapies or biologic agents and malignancy. [23] [24] [25] [26] This comprehensive case-control analysis assessed whether exposure to commonly used systemic psoriasis therapies and biologic agents is associated with an increased risk for malignancy (excluding NMSC).
PATIENTS AND METHODS

Data source and study population
The study design and methodology of PSOLAR have been detailed elsewhere. 27, 28 Briefly, the registry (established in 2007) comprises a long-term, prospective, observational cohort of patients with moderate-to-severe psoriasis (aged $18 years) who were receiving, or were candidates to receive, systemic therapy (including phototherapy) at clinics across North and South America and Europe. Information related to demographic characteristics, disease activity and severity, comorbidities, and psoriasis medication use is collected every 6 months. Planned follow-up for each patient is at least 8 years from registry enrollment. Governing ethical bodies approved the registry protocol, and all patients provided written informed consent. As of the registry cutoff date for this analysis (August 23, 2015), 12,090 registry participants had been followed for a median of 4.17 years, with a maximum follow-up of 8.2 years (total patientyears [PYs] , 48,870).
To calculate risk associated with study therapy, a nested case-control analysis was performed. Cases consisted of patients with newly diagnosed malignancy (other than NMSC) during PSOLAR participation; malignancies in those with a history of malignancy (other than NMSC) were excluded. The date of first malignancy diagnosis is referred to as the index date. Four randomly chosen control patients were matched with each case by age at index date (66 months), sex, geographic region, and enrollment date (61 year). The duration of follow-up for each case was the difference between index date and enrollment date. The index date for the matched control was imputed as the enrollment date for that control plus the index duration of follow-up for the matched case. Matched controls were selected without replacement.
Exposure assessment
For the primary analysis, exposure was defined as having received a dose of study therapy within 1 year of the index date. Exposure was further stratified by duration of therapy into 3 discreet categories for each study therapy: more than 0 months to less than 3 months, 3 months to less than 12 months, and 12 or more months. No exposure (ie, no dose of study therapy within 1 year of the index date) was referred to as 0 months. Exposure to multiple therapies was allowed; patients in each category could have been exposed to other study or nonstudy therapies.
CAPSULE SUMMARY d
Systemic therapy may alter the risk for malignancy in patients with psoriasis. Long-term ($12 months) treatment with TNF-a inhibitor therapy, but not ustekinumab or methotrexate, may increase risk for malignancy.
Malignancy outcomes
Malignancies were considered adverse events of special interest in PSOLAR and were reported by the treating dermatologist and subject to enhanced follow-up efforts. Malignancies were defined as events captured within the Medical Dictionary for Regulatory Activities (version 17.1) system organ class (SOC) neoplasms benign, malignant, and unspecified (including cysts and polyps). First occurrences of malignancy (excluding NMSC) during the registry participation were included here; recurrences or second malignancies in the same patient were excluded. Benign events within this SOC were excluded per study physician review. Any event not categorized in this SOC was considered out of scope. Reported malignancies were coded to Medical Dictionary for Regulatory Activities preferred terms, which were grouped where appropriate, to represent each malignancy subtype. The 5 most common malignancies presented in subanalyses were prespecified on the basis of cumulative rates in all PSOLAR patients; malignancies not captured in 1 of these 5 categories were pooled as ''other'' malignancies in the subanalyses.
Statistical analysis
Analyses were conducted using SAS software, version 9.4 (SAS Institute Inc., Cary, NC). Characteristics were compared between cases and matched controls using the Wald chi-square test. Malignancy incidence rates were expressed per 100 PYs with 95% confidence intervals (CIs). Multivariate conditional logistic regression methodology, adjusted for potential confounding variables known to be associated with malignancy and to influence the selection of the psoriasis therapy, was used to estimate the odds ratio (OR) and 95% CI of malignancy incidence, comparing varying durations of therapy ([0 to \3 months, $3 to \12 months, or $12 months) with no exposure (0 months). Potential confounding variables tested for inclusion in the model were ethnicity, family history of malignancy, body mass index, smoking status, alcohol use, number of comorbidities, psoriatic arthritis, chronic obstructive pulmonary disease, duration of psoriasis, severity of psoriasis, past psoriasis therapy (systemic or phototherapy), and use of other study therapies (eg, the OR for ustekinumab was adjusted for methotrexate and TNF-a inhibitor use). Sensitivity analyses were conducted by defining exposure as 1 or more doses of study therapy within 6 months or 24 months of the index date. We also performed a prespecified sensitivity analysis (the most recent therapy analysis), which attributed malignancy cases only to the systemic therapy immediately preceding the index date, and a post hoc sensitivity analysis (the monotherapy analysis), which excluded cases and controls with exposure to more than 1 therapy in the year before index date.
RESULTS
Overall, 252 PSOLAR participants met the eligibility criteria for malignancy cases; 1008 controls were matched (4:1) to the cases (Fig 1) . The overall incidence rate of first malignancy among patients who did not have a history of malignancy (excluding NMSC) was 0.55 per 100 PYs (95% CI, 0.48-0.62) (total PYs, 46,041). The 5 most frequently occurring malignancies were breast cancer (n = 40), prostate cancer (n = 36), lung cancer (n = 29), melanoma (n = 28), and lymphoma (n = 14). Individual incidence rates were 0.09 per 100 PYs (95% CI, 0.06-0.12), 0.08 per 100 PYs (95% CI, 0.06-0.11), 0.06 per 100 PYs (95% CI, 0.04-0.09), 0.06 per 100 PYs (95% CI, 0.04-0.09), and 0.03 per 100 PYs (95% CI, 0.02-0.05) for breast cancer, prostate cancer, lung cancer, melanoma (including melanoma in situ), and lymphoma, respectively. Other malignancies reported in more than 1 patient were colorectal cancer (n = 14), other cancers (n = 13), endometrial cancer (n = 9), bladder cancer (n = 8), pancreatic cancer (n = 7), renal cancer (n = 6), thyroid cancer (n = 6), hepatic cancer (n = 5), leukemia (n = 5), esophageal cancer (n = 5), head and neck cancer (n = 4), ovarian cancer (n = 4), sarcoma (n = 4), myelodysplastic syndrome (n = 3), myeloma (n = 3), carcinoid tumor (n = 2), and neuroendocrine cancer (n = 2). Table I compares patient characteristics of the 252 malignancy cases with those of the 1008 controls. As expected, some patient characteristics differed between cases and controls (ie, cases showed a higher proportion with family history of malignancy, less alcohol use, a higher proportion with 2 comorbidities, and greater use of phototherapy). Demographics, disease characteristics, and prior treatments were generally comparable between patients who had exposure to study therapies and 12 or more months of treatment yielded a statistically significantly higher risk for malignancy development (OR, 1.54; 95% CI, 1.10-2.15; P = .01) versus no TNF-a inhibitor treatment. When the adjusted analysis was performed for 12 or more months of exposure to an individual TNF-a inhibitor, the results were not statistically significant for infliximab (OR, 1.01; 95% CI, 0.59-1.74; P = .9577), adalimumab (OR, 1.37; 95% CI, 0.93-2.02; P = 1.099), or etanercept (OR, 1.37; 95% CI, 0.94-2.01; P = .1007). However, the point estimates were elevated and the lower limits of the CI was close to 1 for adalimumab and etanercept, suggesting possible elevated risk (Supplemental Table IV ; available at http://www.jaad.org).
When each of the 5 most common malignancies in PSOLAR was considered individually, there was no increased risk for ustekinumab or methotrexate treatment (Supplemental Fig 1; available at http:// www.jaad.org), whereas TNF-a inhibitor treatment for 12 or more months significantly increased the risk for lung cancer (OR, 3.54; 95% CI, 1.15-10.92; P = .028); however, these data were difficult to interpret because of the wide CIs and the low numbers of events.
Results of sensitivity analyses based on varying the definition of exposure before index date (ie, 6 months or 24 months) were generally consistent with those of the primary analysis (12 months) (Table II and Fig 2) . However, the most recent therapy analysis (Table III) and the monotherapy analysis (Table IV) found no significant association between increased risk and treatment for any of the study therapies. Note that in the monotherapy analysis, the total number of cases of malignancy decreased from 252 to 210 (those who had received treatment with more than 1 study agent in the year preceding the index date were excluded).
DISCUSSION
Findings from this large psoriasis registry indicate no increased risk for overall or frequently observed malignancies with any duration of treatment for either methotrexate or ustekinumab when compared with no treatment with these systemic therapies. Treatment with a TNF-a inhibitor There is a relative paucity of data regarding long-term malignancy risk associated with systemic treatment of psoriasis. Current data regarding the malignancy risk associated with methotrexate derives from small series and case studies, 29, 30 and our findings did not indicate an increased risk for malignancy with methotrexate exposure. In the long-term extension of the pivotal PHOENIX I and II trials of ustekinumab, malignancy rates up to 5 years of follow-up remained low and comparable to the expected rate from the National Cancer Institute Surveillance, Epidemiology, and End Results database. 14, 15, 31 As in all randomized trials, however, patients had to qualify for the study on the basis of stringent inclusion and exclusion criteria, and the long-term follow-up included only a limited number of patients; therefore, outcomes for patients in clinical trials may not necessarily be representative of the general population. Nonetheless, these findings from this PSOLAR study, which represents a real-world population, demonstrate no increased risk for malignancy with long-term exposure to ustekinumab, which is consistent with the results from long-term clinical trials.
The potential malignancy risk associated with TNF-a inhibitor use for other indications has been widely studied and debated. An early meta-analysis of rheumatoid arthritis trials found a 3.3-fold increased risk for malignancy with exposure to infliximab or adalimumab 16 ; however, this finding was not replicated in subsequent studies. [17] [18] [19] [20] [21] In psoriasis, the long-term extension of pivotal trials for infliximab, adalimumab, and etanercept [11] [12] [13] have generally shown low and stable rates of malignancy that, in some cases, are comparable to the rates from databases such as the Surveillance, Epidemiology, and End Results database.
In our primary analysis, an elevated risk for malignancy was seen with longer-term exposure to a TNF-a inhibitor (etanercept, adalimumab, and infliximab). By design, this analysis allowed for inclusion of cases/controls with possible exposure to multiple study agents within 12 or more months of the index date, and logistic regression was used to adjust for the effect of multiple exposures. Two sensitivity analyses were conducted to further explore the effect of multiple exposures. The first, which attributed malignancies to the most recent exposure, showed a trend toward increased risk with long-term TNF-a inhibitor exposure; however, the results were not statistically significant. In the second, which excluded malignancies with multiple exposures and reduced the number of cases for consideration, no elevated risk was observed for any of the study agents. The reason for these conflicting results is unclear, although a plausible explanation is that much of the malignancy risk in the TNF-a inhibitor exposure group might be attributed to combination therapy that includes a TNF-a inhibitor. Further studies with a higher number of malignancy , and 24 months of exposure (sensitivity analysis) (C). *The P value comparing malignancy cases with matched controls was significant for TNF-a inhibitor treatment within the 12-month (P = .012), 6-month (P = .028), and 24-month (P = .012) exposure periods.
cases, mutually exclusive groups, and longer follow-up are needed to clarify malignancy risk with long-term TNF-a inhibitor exposure. We chose not to separate individual TNF-a inhibitors (infliximab, adalimumab, and etanercept) in the primary analysis because of the inadequate statistical power of this approach. Additionally, there were a number of cases and controls who switched from one TNF-a inhibitor to another; this cumulative exposure is captured only in the pooled analysis. Nevertheless, the results of the individual TNF-a inhibitor analysis suggest that the elevated risk seen in the pooled analysis (OR of 1.54) was driven by etanercept and adalimumab (ORs of 1.37 for both) rather than by infliximab (OR of 1.01). Also, judging by the higher OR in the pooled analysis versus any of the ORs in the individual analyses, cumulative exposure to a TNF-a inhibitor might be meaningful to malignancy risk. Again, studies with greater power for each individual TNF-a inhibitor are needed to help clarify the risk.
The current study has several key strengths. The study population derives from a longitudinal, disease-based registry of patients recruited from academic, community-based, and hospital-affiliated settings at which therapy is administered per local practice. Thus, the results are generalizable to various real-world practice settings. The casecontrol design, 32 as opposed to a longitudinal cohort design, allows inclusion of all incident malignancies (which are a relatively rare event) and maintenance of power. Also, given that treatment bias may play a role (ie, those patients who were at higher risk for malignancy might have preferentially received long-term systemic therapy), the analytical model adjusted for variables such as duration of disease, psoriasis severity, and past psoriasis therapy. Unlike in previous studies, 4, 8, 9 treatment history was not used as a proxy for disease severity because PSOLAR measures both directly. The analytical model also controlled for other factors that affect malignancy risk, including alcohol use, smoking, and family history of malignancy.
This observational study also has some important limitations. Exposure is not randomized, and despite adjustment for important covariates, it was not possible to control for all treatment bias. In the primary analysis, exposure to concurrent and sequential therapies (by switching) was allowed, meaning cases or controls could belong to 1 or more of the 3 systemic psoriasis therapy categories, and malignancy risk could not be attributed to a single therapy. Information regarding several established malignancy risk factors (eg, occupational exposures, socioeconomic elements, reproductive factors for women, and nonpsoriasis concomitant medications) is not collected systematically in PSOLAR, leading to potential residual confounders. Data collection regarding smoking and alcohol use was limited to information gathered only at registry entry, which lacked quantifiable measures. Not all malignancy cases were confirmed by pathology report or Data for cases and controls are presented as n (%). CI, Confidence interval; n/a, not applicable; TNF-a, tumor necrosis factor-a. *Adjusted for variables found statistically significant in Table I (ie, alcohol use) and for exposure to other therapies (eg, the methotrexate analysis was adjusted for exposure to TNF-a inhibitor and ustekinumab). y P value derived from conditional logistic regression for comparison of malignancy cases versus matched controls.
medical records from the treating oncologist. Finally, the numbers of common malignancy types were small, (n = 14-40), thus limiting the precision of risk estimates for the most frequently occurring individual malignancy types. In summary, the results from this large diseasebased registry of patients with psoriasis treated with systemic therapies provide evidence that neither methotrexate nor ustekinumab increase the overall malignancy risk (excluding NMSC), whereas longer-term TNF-a inhibitor therapy may increase such risk. Additional studies with a larger number of events are needed to further investigate these associations.
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≥3 to <12 mo. >0 to <3 mo. Supplemental Fig 1. Psoriasis. Adjusted odds ratios (ORs) (95% confidence intervals [CIs]) of individual malignancies with exposure in the primary analysis for exposure to methotrexate within 12 months (A), exposure to tumor necrosis factor-a inhibitors (TNF-a) within 12 months (B), and exposure to ustekinumab within 12 months (C).*The P value comparing lung cancer cases with matched controls was significant for TNF-a inhibitor treatment (P = .028). TNF-a, Tumor necrosis factor-a; US, United States.
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Supplemental Table II . Disease characteristics by study therapy and exposure for cases and controls Data for cases and controls are presented as n (%). CI, Confidence interval; n/a, not applicable; TNF-a, tumor necrosis factor-a. *Includes 1 exposure and ustekinumab/methotrexate and adjusted for significant confounders in Table I (ie, alcohol). y P value derived from conditional logistic regression for comparison of each category vs baseline.
